New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2018, Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV
View latest version (2018)Bibliographic Info
GuidelineGuidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
Year of Publication2014
Issuing InstitutionWorld Health Organization
Recommendation
Status
Retired
Recommended in favor
Conditional
Certainty of evidence
Very low
lopinavir/r or atazanavir/r (ATV/r) is recommended as the preferred third drug for HIV post-exposure prophylaxis for adults and adolescents. Where available, RAL, darunavir/r (DRV/r) or efavirenz (EFV) can be considered as alternative options.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
Year2016
InstitutionWHO